BioWorld

April 14, 2006

MGI Submits NDA Seeking FDA Clearance For Saforis

New Channel Mutations Seen As Neurodegeneration Cause

Start-Up Cempra Brings Aboard Optimer's Antibacterial Program

Other News To Note

Appointments And Advancements

Gilead Invests $25M In Corus While Retaining Buyout Option

Gilead Sciences Inc. is putting $25 million into Corus Pharma Inc., and has an option to buy the rest of the respiratory disease-focused firm down the road. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Feb. 9, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 3, 2026